Acknowledgements
CCBIO, HUS, Cancer
CANCER
The authors would like to thank the patients and the following persons who participated in the clinical trial: Bendik Nordanger, Department of Pathology, Haukeland University Hospital (HUS); Ingeborg Winge and Reidun Kristin Kopperud, Centre for Cancer Biomarkers CCBIO, University of Bergen; Andrine Sandøy, Department of Urology, HUS; Hua My Hoang, Rebecca Nguyen, Misbah Sabir, and Jørn Skavland, Department of Clinical Science, University of Bergen; Turid Kirsti Hønnåshagen, Lisbeth Johanne Skoge, and Dag Josefsen, Department of Cellular Therapy, Norwegian Radium Hospital; Ingvill Marie Christensen Curran, Torunn Ervik, Anne Kari Jahn Stephansen, Jannike Lundervik Selen, and Torhild Lahn-Johannessen, Department of Immunology and Transfusion Medicine, HUS; Steffen Hennig and Sigrid Schaper, HS Diagnomics, Berlin; the staff at Clinical Genomics Uppsala at Uppsala University, Sweden. Furthermore, the authors thank Dr. Patrick Juliebø-Jones for help with the linguistic revision.